Krsnaa Diagnostics Limited · NSE:KRSNAA
Krsnaa Diagnostics — Q3 FY2026 Earnings Presentation
21 slides from Krsnaa Diagnostics's earnings presentation, Feb 5, 2026
Slide 1: Stock exchange intimation letter for investor presentation
Date: February 05, 2025 Ref. No.: KDL/SE/100/2025-26 To, To, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, Plot No. C-1, Block G, 25th Floor, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (East) Dalal Street, Mumbai- 400001 Mumbai – 4
Slide 2: Q3 & 9M FY2026 Results Presentation
Q3 & 9M FY2026 Results Presentation One of INDIA’S LARGEST Integrated Diagnostic Service Provider
Slide 3: Disclaimer
Disclaimer This presentation contains statements that are “forward-looking statements”, including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements pertaining to Krsnaa Diagnostics’ future business developments and economic performance.
Slide 4: Krsnaa Diagnostics Limited
DIAGNOSTICS Krsnaa Diagnostics Limited
Slide 5: Krsnaa Diagnostics At a Glance
190 81 CT/ MRI Centres 4,000+ Million+ Patient Collection Centres Patients Served Since Inception Krsnaa Diagnostics At a Glance 140 18 Pathology Labs States/UT Presence in India One of India’s largest NABH accredited Krsnaa Diagnostics is one of the fastest tele-radiology reporting hub with growing
Slide 6: Retail Dynamics
Retail Dynamics Retail Revenue (mn) Retail Revenue Contribution to Group Revenue 10% 177 “Y-o-Y Retail 22 1% Business Q3 FY25 Q3 FY26 Q3 FY25 Q3 FY26 Revenue No. of Touch Points Segment Retail Revenue Mix B2B B2C Increased By 3,101 68% 72% ~8x” 32% 28% 875 Q3 FY25 Q3 FY26 Q3 FY25 Q3 FY26 © Krsnaa Di
Slide 7: 9MFY26 Financial Performance
9MFY26 Financial Performance Particulars 9M FY26 9M FY25 Growth Particulars 9M FY26 9M FY25 Growth Revenue 5,802 5,311 9% EPS 18.2 17.3 5% EBIDTA 1,600 1,416 13% No. of Patient Served 15 14.5 3% EBIDTA Margin 28% 27% 92 bps No. of Test performed 45.4 46.9 (3%) NABL PAT 597 569 5% Accreditation 57 49
Slide 8: Q3FY26 Financial Performance
Q3FY26 Financial Performance Revenue from operation Normalised EBIDTA Normalised PAT Q3FY26 1,812 Q3FY26 484 Q3FY26 168 Q3FY25 1,745 4% Q3FY25 465 4% Q3FY25 169 1% Normalised EBIDTA Margin Normalised PAT Margin No. of Patient Served Q3FY26 27% Q3FY26 9% Q3FY26 4.6 Q3FY25 27% 3bps Q3FY25 10% 4
Slide 9: Launch of 1st Apulki Healthcare Hospital
Launch of 1st Apulki Healthcare Hospital 01 1st PPP Cancer and cardiac care hospital in india 02 150 beds in Association with Pune Municipal Corporation 03 All cancer treatment at CGHS rates under cash and carry model Approval to operationalise 4 more hospitals with capacity of 04 600 beds Designed
Slide 10: Facilities Under Apulki Healthcare Hospital
Facilities Under Apulki Healthcare Hospital 160 Slice Cardiac CT PET CT LINAC © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 9
Slide 11: Facilities Under Apulki Healthcare Hospital
Facilities Under Apulki Healthcare Hospital Dexa X-Ray Mammography © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 10
Slide 12: Q3 FY26 – Centre Growth
Q3 FY26 – Centre Growth CT Centre MRI Centre Tele- Radiology Centre Upon completion of our existing 149 41 order book, we will have 139 39 1,501 200+ CT/MRI centres, 1,434 cementing our position as one of Asia’s Largest Radiology Players. Q3 FY25 Q3 FY26 Q3 FY25 Q3 FY26 Q3 FY25 Q3 FY26 Reference Lab
Slide 13: Competitive Advantages
Competitive Advantages
Slide 14: Driving Excellence Through Quality - India's 1st
Driving Excellence Through Quality- INDIA’S 1ST ACR Recognized Company CAP Accredited Lab NABH Accredited Tele- at Government Facility Radiology Hub Service Excellence Pioneers of Indian Diagnostic Industry © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 13
Slide 15: Quality Multiplied: The Power of 100+ Accreditations
Driving Excellence Through Quality Quality Multiplied: The Power of 100+ Accreditations 57 49 National Accreditation for Board of National Accreditation Board for testing's & Calibration Laboratories Hospitals & Healthcare Providers We are committed to delivering superior quality as our benchmark an
Slide 16: Building India's National Diagnostics Infrastructure
Building India’s National Diagnostics Infrastructure The only listed company in PPP (Public Private 18 states and union Partnership) space with bid territories with penetration till ~81 Mn+ patients served since win ratio of 75%+ tier-II and tier-III towns inception Integrated diagnostic services Qu
Slide 17: Our Pricing - Everyone Can Afford
Our Pricing - “Everyone Can Afford” % lower from Segment Test Competition 1 Competition 2 Competition 3 Krsnaa competitors Radiology CT Brain 4,500 4,500 3,500 880 (75)% Radiology MRI Brain 8,000 8,250 7,000 1,340 (81)% Pathology CBC 250 250 200 37 (82)% Pathology Blood Sugar 85 80 70 20 (71)% Patho
Slide 18: Presence - PAN India
Presence - PAN India Well Diversified Regional Revenue Mix 12% 34% Q3 FY26 42% 12% West South North East India map for representation only, not to scale © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 17
Slide 19: Financial Performance
DIAGNOSTICS Financial Performance
Slide 20: Consolidated Financial Performance
Consolidated Financial Performance In mn Particulars Q3 FY 26 Q3 FY 25 Q2 FY 26 9M FY 26 9M FY 25 Amount % Amount % Amount % Amount % Amount % Revenue from operations 1,812 1,745 2,060 5,802 5,311 Expenses Cost of Material Consumed 391 22% 399 23% 481 23% 1,347 23% 1,277 24% Employee benefits expens
Slide 21: Krsnaa Diagnostics
For further information please contact Krsnaa Diagnostics Vivek Jain, Head- Investor Relations head.investor@krsnaa.in Contact: +91 74107 00645 https://krsnaadiagnostics.com